Esperion Therapeutics (NASDAQ:ESPR) was downgraded by stock analysts at The Goldman Sachs Group from a “neutral” rating to a “sell” rating in a research note issued on Tuesday, Briefing.com reports. They currently have a $24.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $44.00. The Goldman Sachs Group’s price target points to a potential downside of 34.94% from the company’s current price.
A number of other equities analysts also recently commented on the stock. Bank of America downgraded shares of Esperion Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the company from $52.00 to $35.00 in a research note on Friday, January 15th. Credit Suisse Group raised shares of Esperion Therapeutics from a “neutral” rating to an “outperform” rating and set a $45.00 price objective for the company in a research report on Tuesday, November 10th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $72.92.
Shares of NASDAQ ESPR opened at $36.89 on Tuesday. Esperion Therapeutics has a one year low of $23.90 and a one year high of $76.98. The firm has a market capitalization of $1.03 billion, a P/E ratio of -9.58 and a beta of 1.48. The company’s fifty day moving average is $29.20 and its two-hundred day moving average is $32.20.
A number of institutional investors and hedge funds have recently made changes to their positions in ESPR. Wasatch Advisors Inc. lifted its position in Esperion Therapeutics by 93.6% in the 3rd quarter. Wasatch Advisors Inc. now owns 2,409,683 shares of the biopharmaceutical company’s stock worth $89,568,000 after buying an additional 1,165,257 shares in the last quarter. Great West Life Assurance Co. Can grew its stake in shares of Esperion Therapeutics by 12,650.6% in the 3rd quarter. Great West Life Assurance Co. Can now owns 211,660 shares of the biopharmaceutical company’s stock valued at $89,000 after buying an additional 210,000 shares in the last quarter. Rhenman & Partners Asset Management AB increased its holdings in Esperion Therapeutics by 30.2% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 592,225 shares of the biopharmaceutical company’s stock worth $15,398,000 after buying an additional 137,225 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in Esperion Therapeutics by 1,384.7% during the third quarter. BNP Paribas Arbitrage SA now owns 66,040 shares of the biopharmaceutical company’s stock valued at $2,455,000 after acquiring an additional 61,592 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Esperion Therapeutics by 3.2% during the 3rd quarter. State Street Corp now owns 1,802,750 shares of the biopharmaceutical company’s stock worth $67,008,000 after purchasing an additional 55,054 shares during the last quarter.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
Further Reading: What is intrinsic value?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]